A Phase IIa Open Label, Randomized Clinical Trial to Study the Safety and Efficacy of Vintafolide and the Combination of Vintafolide and Paclitaxel Compared to Paclitaxel in Subjects with Advanced Triple Negative Breast Cancer Using Etarfolatide (EC20) Subject Selection
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 31 Dec 2014
Price : $35 *
At a glance
- Drugs Vintafolide (Primary) ; Paclitaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme
- 03 Jul 2014 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 16 Dec 2013 Planned initiation date changed from 1 Sep 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov.
- 16 Dec 2013 Planned End Date changed from 1 May 2016 to 1 Nov 2016 as reported by ClinicalTrials.gov.